The FDA has approved dupilumab (Dupixent) for the treatment of allergic fungal rhinosinusitis, a rare form of chronic sinus inflammation driven by hypersensitivity to fungal organisms in the sinuses, in...
The FDA has approved a nasal antihistamine for nonprescription use in the treatment of seasonal and perennial allergic rhinitis in individuals aged 6 years and older.
